Howard Krauss, MD
Neuro-ophthalmology · Los Angeles, CANPI 1114950060
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AbbVie at 51.0% of the total. Reporting peaked in 2019 at $4,223 and has fallen 75.5% since, to $1,036 in 2025.
Across 90 payments — averaging $81.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Amgen$1K
- AstraZeneca$635
- Acclarent, Inc$197
- Xoran Technologies LLC$196
- Stryker$184
- plus $1K from 21 others
What the payments were for
- Consulting fees$3,60049%
- Travel & lodging$871%
- Food & beverage$3,40846%
- Education$1873%
- Entertainment$521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $3,740 |
| Amgen(2 entities) | 44 | $1,216 |
| AstraZeneca | 6 | $635 |
| Acclarent, Inc | 4 | $197 |
| Xoran Technologies LLC | 4 | $196 |
| Stryker | 2 | $184 |
| Alcon | 2 | $155 |
| Merz Pharmaceuticals, LLC | 1 | $143 |
| Mizuho America, Inc. | 1 | $113 |
| KARL Storz Endoscopy-america | 1 | $92 |
| Argenx US, Inc. | 1 | $75 |
| Omniscient Neurotechnology America Ltd | 2 | $71 |
| Catalyst Pharmaceuticals, Inc. | 1 | $62 |
| Springworks Therapeutics, Inc. | 3 | $60 |
| Optos, Inc. | 2 | $52 |
| Heron Therapeutics, Inc. | 1 | $45 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Merz North America, Inc. | 1 | $35 |
| Dompe US, Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $33 |
| Novartis | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Aerin Medical Inc. | 1 | $21 |
| Biogen | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,335 in reported general payments places this provider in the 70th percentile of 25 neuro-ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $16,327 |
| LumiganBimatoprost | 25 | $11,417 |
| Alphagan PBrimonidine Tartrate | 19 | $8,367 |
| Cyclosporine | 22 | $5,025 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,907 |
| Timolol Maleate | 23 | $3,397 |
| Brimonidine Tartrate | 21 | $2,681 |
| Brinzolamide | 21 | $2,050 |
| Latanoprost | 17 | $138 |
| Dorzolamide Hcl | 20 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $3,740 | $36,11160 claims |
| AlconSimbrinza | $155 | $4,90720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 25 neuro-ophthalmology providers in California.
Other neuro-ophthalmology in Los Angeles
- Frank Abella AyalaLos Angeles$2K
- Alexander EngelmannLos Angeles$429
- Michael GilhooleyLos Angeles$147
- Kimberly CockerhamSan Diego$183K
- Vivek PatelIrvine$81K
- Kimberly GokoffskiOrange$36K
- Syed Khizer KhaderiStanford$35K
- Nafiseh HashemiEncino$12K
- Yin LiuSacramento$11K
- Samuel SpiegelPasadena$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.